NCT05360680 2026-01-22
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Cue Biopharma
Phase 1 Completed
Clinical Trials
10 trialsNCT01827137 2024-09-19
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Sellas Life Sciences Group
Phase 1/2 Completed
NCT02085148 2024-04-22
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
Phase 1 Completed
NCT03149003 2023-11-15
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT02498665 2023-11-14
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02982941 2022-02-08
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
MacroGenics
Phase 1 Completed
NCT01222780 2020-01-18
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01621542 2019-07-17
Clinical Study of WT2725 in Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT01169584 2016-01-21
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
SillaJen, Inc.
Phase 1 Completed
NCT01598454 2015-07-29
Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
Laboratorio Elea Phoenix S.A.
Phase 1 Completed